Top Links

Articles Related to leukemia

Adverse Drug Events and Predictors of One Year Survival among Adult Patients with Acute Myeloid Leukemia in a Kenyan Tertiary Health Facility

Treatment of acute myeloid leukemia is a challenge because of the adverse drug events associated with therapy and the heterogeneous nature of the subtypes. Research on improving overall survival of patients based on different regimens, reduction of adverse dug events, clinical characteristics and the type of acute myeloid leukemia is critical.
View complete article: PDF  |  Full-text

Blastic Plasmacytoid Dendritic Cell Neoplasm Presenting as a Harbinger of Acute Myeloid Leukemia

A 51 year old female was referred to our dermatology clinic for a rapidly growing lump on head of 6 weeks duration. On examination we observed a 15 cm diameter erythematous crusted tumor on the forehead with significant bilateral cervical lymphadenopathy. An excision biopsy of the tumor revealed a malignant high grade diffuse undifferentiated infiltrating neoplasm involving the skin and subcutaneous tissue.
View complete article: PDF  |  Full-text

Treatment of Chronic Myeloid Leukemia with Imatinib: A Study of 48 Cases in Burkina Faso

The purpose of the study was to evaluate the management of patients treated with Imatinib for Chronic Myeloid Leukemia (CML) in the Department of Clinical Hematology of the Yalgado OUEDRAOGO University Hospital in Ouagadougou, Burkina Faso.
View complete article: PDF  |  Full-text

Degree of Malignancy of T-Cell Acute Lymphocytic Leukemia Related to Autofluorescence in an EL4-Based Model

T cell acute lymphocytic leukemia (T-ALL) is an aggressive hematologic malignancy in terms of its pathology and populations. It is important to understand the phenomenon of autofluorescence in living cells because normal and cancer cells can be distinguished by this feature. However, the autofluorescence link to T-ALL is poorly understood.
View complete article: PDF  |  Full-text

How to select Tyrosine Kinase Inhibitor for the patients with newly diagnosed Chronic Myeloid Leukemia?

The clinical outcomes of chronic myeloid leukemia (CML) have been improved by tyrosine kinase inhibitors (TKIs). However, there is no established consensus for TKI selection in de novo CML. We investigated TKI treatment patterns in a real-world setting. Among 95 chronic-phase CML patients, 44% were initiated treatment with imatinib, 26% with dasatinib, and 30% with nilotinib. Our data suggest that imatinib remains applicable and that dasatinib has a favorable therapeutic effect, although pleural effusion can arise. Nilotinib was the most prevalent TKI as the treatment-associated adverse events were deemed more manageable than those associated with imatinib and dasatinib.
View complete article: PDF  |  Full-text

Tomotherapy Treatment of Chronic Lymphocytic Leukemia and Ocular Lymphoma

A sixty-five-years-old male patient with history of non-Hodgkin’s lymphoma of the right orbit and a fifty-years-old female patient with chronic lymphocytic leukemia with peripheral lymphocytosis were treated on TomoTherapy. In the first case, a 1 cm beam was used for planning a delivery of 30.6 Gy in 17 fractions with a sequential boost of 9 Gy in 5 fractions. Tumor involvement of the ipsilateral lens and lacrimal gland in the planning target volume necessitated a compromise between preserving patient’s vision and delivery of tumoricidal dose to the target. In the second case, 30 Gy in 20 fractions delivery was planned with a 2.5 cm beam. The tumor extended anteriorly and this technique allowed sparing more orbital tissue and required a high modulation factor.
View complete article: PDF  |  Full-text

Prevalence of the different FAB sub type of Acute Myeloid Leukemia related to hematological parameters in Sudanese

Acute myeloid leukemia (AML) is a heterogeneous disease. Therefore, various parameters are needed to classify this disease into subtypes. The commonly used method for diagnosis and classification is based on FAB criteria using morphology and cytochemical stains. For some of the categories, immunopheno typing is necessary. The aim of present study is to determine the frequency of various sub-types in acute myeloid leukemia using FAB criteria in our Sudanese population. This will aid in the correct diagnosis of acute leukemia and hence proper management of the patients.
View complete article: PDF  |  Full-text

Acute Myeloid Leukemia Mimicking as Acute Megakaryoblastic Leukemia

Down syndrome or constitutional trisomy 21 was linked to leukemia for the first time in a case report published in 1930 since then, down syndrome has been recognized as one of the most important leukemia – predisposing syndromes and patients with down syndrome and leukemia have unique clinical features and significant differences in treatment response toxicity profiles compared to patients without down syndrome.
View complete article: PDF  |  Full-text

Responses and Survival under Pegylated Interferon α2a Treatment for Patients with Post-MPN Acute Myeloid Leukemia and Acute Panmyelosis with Myelofibrosis

We report here for the first time the efficacy of pegylated interferon α2a (Peg-Ifn) as a therapy for patients with myelofibrosis and high blast counts. We treated four patients who were in an accelerated phase of myeloproliferative neoplasms or acute panmyelosis with myelofibrosis using only this drug.
View complete article: PDF  |  Full-text

Observations on Aeromonas Infection in 7 Patients with Acute Leukemia

Aeromonas infections in humans are becoming increasingly frequent. They have the potential to infect humans and are associated with a variety of illnesses, such as enterocolitis, septicemia, skin and soft tissue infectious and peritonitis.
View complete article: PDF  |  Full-text

Microwave and Magnetic (M2 ) Proteomics of Childhood B-ALL

We hypothesized that quantitative tandem mass spectrometry-based proteomics, incorporating rapid microwave and magnetic sample preparation (M2 proteomics), might enable relative protein expression to be correlated to childhood B-precursor acute lymphoblastic leukemia (B-ALL) cytogenetic subtypes, corresponding to low-risk (ETV6-RUNX1) and high-risk (MLL-R) subtypes.
View complete article: PDF  |  Full-text

Vasculitis Associated with Chronic Lymphocytic Leukemia

A patient is present who has chronic lymphocytic leukemia (CLL) and developed a vasculitis involving the skin and large vessels along with immune complex mediated glomerulosclerosis. Both vasculitis and immune complex nephritis are rare manifestations of CLL.
View complete article: PDF  |  Full-text

Development of the Analytical Model for the Assessment of the Efficiencies of Different Therapeutic Modalities in Leukemia

Different therapeutic regimes like chemotherapy, cytokine based immunotherapy and/or stem cell transplantation are generally be the suggested options for treatment of leukemia. However, the selection of the best therapeutic strategy for an individual patient remains uncertain till now
View complete article: PDF  |  Full-text

The Emergence of Multiple Myeloma in a Patient with Essential Thrombocythemia: A Case Report

Multiple myeloma is a neoplastic disease characterized by neoplastic proliferation of plasma cells and monoclonal protein expression and related tissue damage.In the presence of overt clinical signs, the disease can easily be diagnosed, however in order to diagnose atypical cases, further investigation is needed with high clinical suspicion.
View complete article: PDF  |  Full-text

m6a RNA Methylation: The Implications for Health and Disease

The recent resurgence of interest in m6A has been spurred by some intriguing findings detailing the effects and dynamics of this epigenetic modification. The m6A modification is a highly reactive and fluid modification which can respond rapidly to a broad variety of stimuli, and translate these signals into cellular activity. The little information that has been established on its functional capacity has opened up many new avenues of research and has tremendous implications for several fields of study.
View complete article: PDF  |  Full-text


Editorial Board Members Related to leukemia

Xiaoyan Jiang

Professor
Department of Medical Genetics
University of British Colombia
Canada

Daniel Lacorazza

Associate Professor
Departments of Pathology and Immunology
Baylor College of Medicine
United States

David J. MacEwan

Professor
Department of Molecular & Clinical Pharmacology
Institute of Translational Medicine
University of Liverpool
United Kingdom

Julie Teruya-Feldstein

Director
Hematopathology
Immunohistochemistry Laboratory
United States

BRUCE D CHESON

Professor of Medicine
Division of Hematology and Oncology
Georgetown University Hospital
United States

PREET M. CHAUDHARY

Professor
Department of Medicine
University of Southern California
United States

Martin Falk

Head and Professor
Institute of Biophysics of ASCR
Czech Republic

Lan Zhou

Assistant Professor
Department of Pathology
Case Western Reserve University
United States

Grant Dewson

Laboratory Head
Cell Signalling and Cell Death Division
Walter & Eliza Hall Institute of Medical Research
Australia

Anthony Joseph Berdis

Assistant Professor
Departments of Chemistry and Biology
Cleveland State University
United States
Submit Manuscript


Open Access Journals

View All Journals